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Abstract
Background Consumer Medicine Information (CMI) is a brand-
speciﬁc and standardized source of written medicine information
available in Australia for all prescription medicines. Side-eﬀect
information is poorly presented in CMI and may not adequately
address consumer information needs.
Objective To explore consumer opinions on (i) the presentation of
side-eﬀect information in existing Australian CMI leaﬂets and
alternative study-designed CMIs and (ii) side-eﬀect risk informa-
tion and its impact on treatment decision making.
Design Fuzzy trace, aﬀect heuristic, frequency hypothesis and cog-
nitive-experiential theories were applied when revising existing
CMI side-eﬀects sections. Together with good information design,
functional linguistics and medicine information expertise, alterna-
tive ramipril and clopidogrel CMI versions were proposed. Focus
groups were then conducted to address the study objectives.
Participants and setting Three focus groups (n = 18) were con-
ducted in Sydney, Australia. Mean consumer age was 58 years
(range 50–65 years), with equal number of males and females.
Results All consumers preferred the alternative CMIs developed
as part of the study, with unequivocal preference for the side-
eﬀects presented in a simple tabular format, as it allowed quick
and easy access to information. Consumer misunderstandings
reﬂected literacy and numeracy issues inherent in consumer risk
appraisal. Many preferred no numerical information and a large
proportion preferred natural frequencies.
Conclusions One single method of risk presentation in CMI is
unable to cater for all consumers. Consumer misunderstandings
are indicative of possible health literacy and numeracy factors
that inﬂuence consumer risk appraisal, which should be explored
further.
doi: 10.1111/hex.12215
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Introduction
Medicine information helps increase consumer
understanding, address consumers’ information
needs and assist in informed decision mak-
ing.1,2 Consumers have considered written
medicine information (WMI) as an important
and reliable source of medicine information.3
Written resources may help to reinforce medi-
cine information that is diﬃcult to recall, such
as side-eﬀects and dosages.4
Consumers seek side-eﬀects information,
alongside other information critical for safe
medicines use.5–7 There is therefore a need for
detailed, comprehensive side-eﬀects and medi-
cine safety information to be made available
for consumers at a level that they can under-
stand.8,9 Speciﬁcally, side-eﬀects and the likeli-
hood of experiencing a side-eﬀect is highly
coveted by consumers,10,11 where the need for
their inclusion in WMI is recognized.12 Previ-
ous work has noted that consumers prefer side-
eﬀects to be categorized according to likelihood
and severity12, where some have felt that side-
eﬀects information presented in its entirety will
help facilitate informed treatment decision
making.8
Numerical and verbal descriptors can be
used to present side-eﬀect risk information in
WMI. Risk overestimation has been associ-
ated with verbal descriptor use (e.g. common
and rare),13–15 where there is room for error
when consumers translate this information
into numerical terms.16 Numerical descriptors
have been favoured for the use in WMI,12
where absolute (natural) frequencies (e.g. three
in 100 people will experience a side-eﬀect) has
led to increased consumer satisfaction in com-
parison with verbal descriptor use17 and have
on the whole supported more accurate con-
sumer risk estimates compared with frequency
bands (e.g. less than 1 in 100 people but more
than 1 in 1000 people will experience a side-
eﬀect).18 However, consensus has not been
reached on a superior numerical descriptor
that promotes accurate consumer understand-
ing. A similar proportion of accurate
consumer side-eﬀect risk estimates were seen,
when presented as either percentages or fre-
quencies.19
Beneﬁt–risk information may lead to treat-
ment reservations for some and empowerment
in treatment decision making for others.20 Con-
sumer appraisal of beneﬁt–risk information
thereby plays an important role, as it can
impact intended treatment decision making.21
The impact of risk information presentation
(such as framing eﬀects demonstrated through
positive framing use, which fuelled consumer
preference for a particular treatment22) coupled
with consumer overestimation of risk16,19,23
highlights the complexities of side-eﬀect risk
presentation in WMI.
Side-eﬀect risk information appears to have
been poorly presented in a proportion of
WMI.24 Moreover, studies have explored the
use of risk descriptors (as isolated text
separate to other text normally found in
WMI) without contextualization within WMI
as a complete medicine information
source,15,16,18,19,23,25,26 signalling the need for
further work. Moreover, psychological models
relevant to risk communication and percep-
tion remain neglected when reformatting and
revising WMI.
In Australia, there is a legal requirement
for pharmaceutical manufacturers to supply
Consumer Medicine Information (CMI) with
all prescription and pharmacist-only medicines
(over the counter medicines that are required
to be handed out by the pharmacist).27 CMI
are brand-speciﬁc and standardized sources of
WMI, whose content is guided by legislation.
They are used by consumers as an important
source of medicine information.5,7 However,
there are limited Australian studies that have
sought to discern consumers’ views speciﬁcally
on side-eﬀects information in CMI leaﬂets.
Therefore, this study aimed to explore consum-
ers’ opinions on (i) the presentation of side-
eﬀects information in Australian CMI leaﬂets
and (ii) side-eﬀect risk information and its
impact on their treatment decision-making pro-
cesses.
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Methods
This study comprised of two stages:
1. Reformatting and revising the CMI side-
eﬀects sections for ramipril (Tritace brand;
Sanoﬁ-Aventis Australia Pty Ltd, Macquarie
Park, Australia) and clopidogrel (Plavix
brand; Sanoﬁ-Aventis Australia Pty Ltd,
Macquarie Park, Australia).
2. Qualitative exploration of consumer opin-
ions, understanding and decision-making
processes relating to side-eﬀects and side-
eﬀect risk information.
Stage 1: Reformatting and revising the CMI
side-effects sections
Psychological model selection
Appropriate psychological models acted as the-
oretical frameworks underpinning the refor-
matting and revising of the side-eﬀects section
of the existing (original) CMI for ramipril (last
revised 2007 by the pharmaceutical company/
sponsor) and clopidogrel (last revised 2009),
postulated to help promote accurate consumer
risk appraisal and account for subjective risk
perception.
Models were selected according to their
appropriateness of application to WMI and rele-
vance to risk perception and communication.
Fuzzy trace,28,29 aﬀect heuristic,30–32 frequency
hypothesis28 and cognitive-experiential33 theo-
ries were chosen. In conjunction with the princi-
ples of good information design, functional
linguistics and medicine information expertise,34
four alternative CMI versions were produced
for each study medicine (Table 1).
Selected models and considerations
Selected models were used in combinations to
support consumer understanding, where each
had certain strengths and weaknesses when
applied to side-eﬀect risk communication in
WMI (Table 2).
Fuzzy trace theory. Percentages were chosen to
convey side-eﬀect risk information, under-
pinned by fuzzy trace theory (FTT), due to a
reported consumer desire for percentages34
and risk appraisal accuracy in relation to
percentages.35 Furthermore, to help promote
the intended gist (side-eﬀects will not be experi-
enced by the majority), positive framing (likeli-
hood of not experiencing a side-eﬀect) was used
in V2 to support consumers’ gist formation
(Table 1). The intended gist was proposed to
target widespread consumer overestimation of
risk associated with verbal descriptor use.13–15
The aﬀect heuristic. Beneﬁt information is
expected to impact an individual’s subjective
view (aﬀect) and therapy decision making.
Consumers want positive information provided
before side-eﬀects9 as well as beneﬁt–risk infor-
mation.12 Therefore, in V2, both beneﬁt and
side-eﬀect risk information were provided con-
comitantly (Table 1). The integration of beneﬁt
information into the beginning of the side-eﬀects
section was predicted to supplement the positive
framing and aid balanced decision making.
The frequency hypothesis. As frequency hypoth-
esis (FH) assumes that consumers have direct
experience with natural frequencies and predicts
ease of understanding in comparison with artiﬁ-
cial constructs such as normalized probabilities
or decimals,33 all probabilities were presented
as natural frequencies in V4 (Table 1).
Cognitive-experiential theory. Experience with
smaller numbers, as opposed to larger ones
(i.e. denominators), indicates that consumers
have preferential bias towards smaller numbers.
Therefore, when applying FH and cognitive-
experiential theory (CET) to V4, frequencies
were expressed using the smallest denomina-
tors, where possible (Table 1). However, large
denominators were unavoidable and have been
utilized where smaller denominators were not
meaningful.
Sourcing and use of numerical side-eﬀect risk
information
Numerical side-eﬀect risk information for
clopidogrel was sourced from the CAPRIE
study data presented in the Australian
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clopidogrel Product Information (PI).36 Due to
limited numerical data in the Australian ramip-
ril PI, relevant ﬁgures were extracted for use
from the FDA ramipril (Altace brand) pre-
scribing information.37
All numerical ﬁgures identiﬁed and used
were rounded to the nearest whole number.
Side-eﬀects that had no distinct numerical risk
estimate were matched to the verbal descriptor
used to describe their likelihood in the PI. The
numerical range that deﬁned the corresponding
descriptor was then included in the reformatted
and revised side-eﬀects sections where appro-
priate (e.g. ‘less common’ equated to 2% and
less, which was then reported for that speciﬁc
side-eﬀect). ‘Likelihood unknown’ was quoted
when numerical side-eﬀect risk information
was unavailable or could not be matched to a
side-eﬀect in the PI.
Stage 2: Qualitative exploration of consumer
opinions, understanding and decision-making
processes
A qualitative exploration was undertaken to
address the study objectives.
Choice of qualitative method
Focus groups were chosen because they can
help clarify concepts and promote the
Table 2 Strengths and weaknesses relevant to the model application in the CMI reformatting and revising process
Model/theory Description of model/theory Strengths Weaknesses
Fuzzy trace (FTT) Dual-process theory comprising
two information representations:
verbatim (literal aspect) and gist
(interpretation or understanding
of presented information)28,29
Consumers encode information
using both gist and verbatim
representations; gist
representation is emphasized as
the advanced encoding process
Established extrapolation to
health risk communication
and perception28,29
Pertinent to medical decision
making29
Does not provide as much
detail regarding a preferred
numerical descriptor to
communicate risk and help
consumers perform gist
encoding
Affect heuristic
(AH)
Subjective responses are critical
to decision making30–32
Perceived benefit and risk
are intrinsically linked
Able to account for subjective
perception of risk30–32
Provides rationale for inclusion
of benefit information, but
unable to provide a detailed
framework for the
reformatting and revising of
side-effects sections on its
own
Frequency
hypothesis (FH)
Computational approach,28
supportive of reduced
computations required to be
performed by a consumer to
gauge meaning
Predicts natural frequencies
are easier to understand as
consumers have direct
experience with them
Can be used to select a
numerical risk descriptor
(natural frequencies) which
can theoretically aid
consumer understanding33
Does not necessarily provide
detailed projections regarding
consumer decision-making
processes
Cognitive-
experiential
theory (CET)
Recognizes individual differences
inherent in information
processing33
When applied, CET suggests
preferential consumer bias
towards smaller numbers
(denominators) due to prior
experience
Accounts for individual
differences in the processing
of information33
Explains favouring of smaller
numbers over larger
numbers33
Limited literature supporting
application to health risk
communication and in
particular to written medicine
information
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generation of hypotheses and are useful when
examining consumer perceptions, attitudes and
behaviour.38 The group dynamic may be con-
ducive to the conception of novel insights.39
Focus group participants and logistics
Participants were recruited using a market
research company, where potential participants
were identiﬁed from their consumer database
to meet the study inclusion criteria. A recruit-
ment brief, outlining the project objectives and
inclusion criteria, was provided to the company
to guide the recruitment process. Participants
had to be as follows:
1. Aged 50 years or above.
2. Currently taking at least one prescription
medicine or have taken so in the last
6 months.
3. Able to participate without needing a trans-
lator.
4. Not currently taking the study medicines
(ramipril and clopidogrel).
Ramipril and clopidogrel CMIs were pro-
vided to participants 1–2 weeks prior to the
focus groups. Participants were provided with
the participant information statement and
consent form on the day, in addition to a
demographic questionnaire. Consumers were
compensated $50 (Australian Dollars) for their
participation.
Three focus groups of six participants (total
18 participants) lasting 1–1.5 h were conducted
in Sydney, Australia (theoretical saturation of
ideas40 was attained by the third focus group).
Mean participant age was 58 years (range 50–
65 years), with equal number of males and
females. English was the main language spoken
at home, with the majority of participants
attaining a Higher School Certiﬁcate (year 12)
or lower level of education.
Group discussion protocol and data analysis
Discussions were structured to explore con-
sumer thought processes when making therapy
decisions in response to medicine information
provided. Consumers were asked for their
opinions, understanding and decision-making
processes in response to the alternative CMIs
presented. Questions were also incorporated to
examine each psychological model’s appropri-
ateness to actual consumer risk appraisal (as
opposed to predicted consumer risk appraisal).
Speciﬁcally, consumers were asked to explain
their understanding of the side-eﬀect risks
described.
Each focus group was audio-recorded, with
the consent of all participants, and transcribed
verbatim. Thematic analysis was conducted
independently by two researchers, with emer-
gent themes discussed and agreed upon to
ensure identiﬁcation of all themes.
This study received approval from the Uni-
versity of Sydney Human Research Ethics
Committee.
Results
Consumer responses from the focus groups
were broadly categorized into the following: (i)
ﬁndings related to the formatting and layout
changes in both existing and alternative CMIs
and (ii) consumers’ interpretation of the side-
eﬀects information in the original and revised
alternative CMIs.
Consumer perspectives – format and layout
Every consumer preferred at least one of the
alternative CMIs to the existing original CMI,
particularly the two-column design (instead of
the three-column design adopted by original
CMI). Consumers felt that the small font size
used in existing CMI was diﬃcult to read. Fur-
thermore, some consumers also expressed that
the CMI content was overwhelming, in part
due to long lists of information.
Conversely, consumers liked appropriate bol-
ding for emphasis and bullet points. Consum-
ers preferred side-eﬀects to be categorized
according to severity, where one consumer pre-
ferred categorization in order of ascending
severity and others preferred similar side-eﬀects
to be grouped together.
There was an overwhelming preference for
V1, where consumers found the tabular format
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more acceptable, simple, understandable and
easier to navigate. Consumers noted that it was
easier to ﬁnd the action needed to be taken,
highlighted through the tabular format.
I like it because I go straight back to fault ﬁnd-
ing in car manuals and that’s what you’ve done
here. It gives you a problem and how to ﬁx it
(Focus Group 1 (FG1), Participant 5 (P5))
Interestingly, consumers did not recognize
that the side-eﬀects were alphabetized or
ordered according to likelihood until
prompted.
Understanding of side-effects information
Consumer understanding of the terminology
utilized to convey side-eﬀects information ﬂuc-
tuated signiﬁcantly, where particular terms
were susceptible to consumer misunderstand-
ing. Problematic terms included side-eﬀects,
likelihood and severity, in addition to ‘likeli-
hood unknown’.
Side-eﬀects
Consumers had diﬃculty distinguishing
between symptoms, side-eﬀects and allergies,
where one consumer commented that the side-
eﬀects ‘yellowing of the skin’ and ‘dry cough’
were an allergy and intolerance, respectively.
Interestingly, side-eﬀects were not always
negative, where side-eﬀects such as weight loss
were deemed favourable, increasing consumers’
willingness to take a medicine in light of these
‘positive’ side-eﬀects. Conversely, high per-
ceived severity resulted in decreased willingness
to take the medicine.
Likelihood and severity
Consumers were confused and unable to deﬁne
likelihood and severity.
It says very serious side eﬀect. . . and then they
say 97% (will) not (be) experiencing this side
eﬀect. Why would this one be a very serious side
eﬀect? (FG2P1)
Likelihood and severity were used inter-
changeably by consumers. One consumer
correlated severity with the action needed to be
taken. Another consumer correlated ‘very
serious’ side-eﬀects with a high likelihood, and
others believed the opposite. Severity was sub-
jective, where more serious side-eﬀects
increased consumer concern and caused
disagreement in the classiﬁcation of certain
side-eﬀects.
A proportion of consumers did not under-
stand ‘likelihood’. ‘Likelihood’ was interpreted
as the time of onset of the side-eﬀect, where
one focus group reached consensus that a dry
cough and yellowing of the skin would occur
within 12 and 48 h, respectively. Common
side-eﬀects were perceived to have a fast time
of onset. When asked, an overwhelming major-
ity was unable to provide a numerical risk
estimate for speciﬁc side-eﬀects. However, con-
sumers acknowledged risk variation and the
concept of individual risk levels, where side-
eﬀect risk was dependent upon factors like ‘the
health level of the person’ (FG1P2) and exist-
ing allergies.
Likelihood unknown
Consumers were strongly opposed to the use of
‘likelihood unknown’ and regarded it as illogi-
cal. Consumers believed that these side-eﬀects
were included due to legal obligation and were
pharmaceutical manufacturers’ eﬀorts to pre-
vent consumers from seeking legal action if
side-eﬀects were experienced. It caused distrust,
where incompetency and the need for further
studies were implied.
No way. That [likelihood unknown] shows igno-
rance and non-testing. (FG1P4)
When asked what ‘likelihood unknown’
meant, one consumer stated that ‘the likelihood
is inﬁnity’ (FG2P6). Conversely, ‘one in a mil-
lion’ (FG3P5) was suggested by another con-
sumer to represent a small side-eﬀect risk in
relation to ‘likelihood unknown’.
Understanding and opinions of numerical
side-effect risk information
Diversity in consumer opinions and understand-
ing of numerical side-eﬀect risk information is
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a core ﬁnding. The use of natural frequencies,
percentages and positive framing had varying
impacts upon the consumers.
Consumer opinions regarding numerical side-
eﬀect risk information
Numerical side-eﬀect risk information worried
some consumers. The presence of numerical
information caused distrust and was dismissed
as an inaccurate representation of true likeli-
hood of occurrence. Consumers were more
focused on determining individual side-eﬀect
risk, as opposed to relying on population side-
eﬀect risk.
I’ve had two drug reactions and I think really
when it happened to me, I didn’t think that. As
you know, our bodies and our genetics are diﬀer-
ent. Something in those two things didn’t agree
with me but it doesn’t mean it wouldn’t agree
with you. (FG3P6)
One consumer questioned the appropriate-
ness of the extrapolation of data derived from
testing to the general population, where ‘they
might be using a group of 1000 people and it is
going out to millions of people’. (FG2P6)
Natural frequencies
A large proportion of consumers preferred nat-
ural frequencies included in V4. Consumers
stated that it was not ‘natural’ to think in
terms of percentages, where natural frequencies
required less computational processes.
Yeah, I don’t like working in percentages. I’m
lazy. Just to say three in a hundred suits me.
(FG3P2)
Overall, consumers wanted to know the test
population size from which the risk values were
derived. Natural frequencies were perceived to
provide this, as they were easily associated with
distinct patient population numbers. Conse-
quently, natural frequencies embodied more
certainty and speciﬁcity for consumers in com-
parison with percentages.
Three in 100 is more narrowing (because for)
every 100, there is only three. But 3%, it could
be as a mass but then they take the average.
(FG2P1)
Natural frequencies provided a realistic
dimension to risk, where a denominator of 100
was interpreted literally as a small sample size
in comparison with the total population. Con-
sumers assumed that the denominator corre-
lated with the ﬁxed sample size from which the
information was derived. Similarly, when the
risk of a side-eﬀect was reported as in one in
10 000, a consumer commented:
At least 10 000 [people] have got to be on that
drug before they can make a claim like that.
(FG3P5)
Furthermore, the numerator was also a
source of concern. One consumer (a caregiver
of her adult daughter who experienced life-
threatening side-eﬀects) commented:
Less than one in ten thousand; well that is not
much is it? But you wouldn’t want to be that
one. (FG2P4)
Despite the low likelihood of one in 10 000
experiencing this very rare side-eﬀect, appre-
hension about being this one person dissuaded
the consumer from taking the medicine.
Overall, consumers agreed that natural fre-
quencies were a more appropriate way to pres-
ent smaller likelihoods, as whole numerators
and denominators were easier to understand,
as opposed to a small percentage containing a
decimal (e.g. 0.01%). However, larger and
non-uniform denominators utilized in an alter-
native Plavix CMI version caused confusion
for some consumers.
Percentages
Percentages, included in V2 and V3, were pre-
ferred by a smaller proportion. Some consum-
ers reported percentages to be easier to
understand, whereas others thought the oppo-
site. Percentages indicated to consumers that
the sample population size could vary and was
perceived to ‘turn us [consumers] into com-
modities’ (FG1P2).
A key ﬁnding was consumers’ perceived non-
equivalence between numerical risk descriptors.
Consumers were unsure of whether it was pos-
sible to translate percentages into equivalent
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natural frequencies accurately. One consumer
incorrectly emphasized that percentages were
averages and therefore not equivalent to natu-
ral frequencies.
It depends if you look at it as an average, an
average of 3%. Maybe 200 will only have one
(who experiences the side eﬀect) and 100 would
have four or ﬁve. (FG2P1)
Positive framing and numeracy
Positive framing use, as seen in V2 and V3,
decreased worry for some consumers whilst
others found it disconcerting. Positive framing
of numerical side-eﬀect risk information
appeared to increase consumer willingness to
take a medicine.
What it [positive framing] does to me is negate all
the side eﬀects. There’s 99, 99, [and] only one is
92; and so you’re not going to get it and people
will take it anyway, that’s what I think. . . He’s
the only one who puts himself in the 3%. 99% of
the people think they’re normal. (FG3P1)
Interestingly, consumers who could easily
interconvert between positively and negatively
framed risk information were less susceptible
to framing eﬀects. Furthermore, individual per-
ceptions superseded framing eﬀects for some,
where one consumer’s own perceived individual
risk was high regardless of framing.
With my luck, I’ll be in the 3% so it doesn’t
matter. (FG3P5)
Consumers tended to ignore table headings
which gave rise to misinterpretation and worry.
When I look at this, I saw the ﬁgure and per-
centage and didn’t go on to read it. . . I saw it as
that’s your chances of getting it and it should be
round the other way. (FG1P5)
Moreover, some found it diﬃcult to relate
positively framed side-eﬀect risk information to
individual risk, preferring negatively framed
side-eﬀect risk information.
Yeah and it’s obvious that 97 and 99 look better
than three or two. But in this case, if you want
to know that it’s not going to aﬀect you, you
would rather see the lower number than the big-
ger number. (FG2P6)
Inclusion of benefit information
Beneﬁt information included only in V2 went
unnoticed by consumers. However, when
prompted, consumers expressed that it gave
them the rationale and conﬁdence to take the
medicine. Perceived beneﬁt outweighing risk
and potential improvement in quality of life
increased willingness to commence treatment.
Whilst autonomous consumers were willing to
take ramipril in light of the beneﬁt informa-
tion, the magnitude was insuﬃcient to shift
some consumers’ unwillingness to take ramip-
ril. Additionally, consumers reliant upon their
doctor for therapy decision making were
unwilling to commence treatment unless
deemed necessary by their doctor.
Although some wanted numerical beneﬁt
information, consumers acknowledged that
beneﬁt information without numerical ﬁgures
led to increased perceived beneﬁt of a medi-
cine.
Because it could be 20% instead of 3%, they
shouldn’t put the percentage in it. (FG2P2)
Discussion
A broad spectrum of consumer opinions was
evident, where the majority preferred the sim-
ple tabular format in V1. The term ‘side-eﬀect’
was at times misconstrued. Additionally, con-
fusion between ‘likelihood’ and ‘severity’ was
prominent, where the majority had diﬃculty
estimating the likelihood of experiencing side-
eﬀects. Signiﬁcant individual variation in risk
appraisal was apparent, which may contribute
to diﬀerences in consumer preferences for the
alternative CMI versions. Speciﬁcally, a supe-
rior, preferred and correctly understood
numerical descriptor did not emerge.
Consumer perspectives – format and layout
The positive impact of the application of good
information design, functional linguistics and
medicine information expertise was evidenced
by all consumers preferring at least one of the
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alternative CMIs, with positive consumer feed-
back provided on the revised layout. Due to
the overwhelming preference for tabulated
side-eﬀects (in V1 speciﬁcally), its feasibility in
future WMI redevelopment and optimization
should be considered. Earlier work has demon-
strated that a redeveloped WMI leaﬂet for
Mersyndol (Sanoﬁ-Aventis Australia Pty Ltd,
Macquarie Park, Australia), which included a
side-eﬀect table, performed better than the
existing CMI when user tested to examine con-
sumers’ ability to locate and understand infor-
mation.34 Furthermore, the ﬁndings of Tait
et al.41 highlighted that tables presenting bene-
ﬁt and risk information promote the encoding
of gist and verbatim representations in individ-
uals with low literacy and numeracy, thus rein-
forcing the advantages of tabulating side-
eﬀects and side-eﬀect risk information. How-
ever, Hawley et al.42 found that tables were
only superior in promoting verbatim under-
standing. Accordingly, diﬀerences in table lay-
out may account for diﬀerences in gist and
verbatim understanding and should be
explored in further detail.
Side-effects information
Consumers found it diﬃcult to distinguish
between a side-eﬀect, allergy and symptoms of
a medical condition, where ‘likelihood’ and
‘severity’ were also used interchangeably.
Health literacy, deﬁned as ‘the ability to
access, understand, evaluate and communicate
information as a way to promote, maintain
and improve health in a variety of settings
across the life-course’ (p. 11),43 is integral to
an individual’s ability to interpret and gain
meaning from WMI,44 where sound health lit-
eracy is linked to increased awareness of the
risk of experiencing medicine-speciﬁc side-
eﬀects.45 Consequently, literacy and/or health
literacy issues that can aﬀect consumer under-
standing must be considered in WMI develop-
ment. For example, current CMI incorporates
allergic reaction signs and symptoms within
the side-eﬀects section, which may contribute
to consumers’ inability to distinguish between
the two. A separate subheading for allergy
information may be advantageous to promote
vigilant monitoring, whilst preventing confu-
sion, and may improve consumer health literacy.
Understanding and opinions of numerical side-
effect risk information
Consumer misunderstanding of the non-equiva-
lence between percentages and natural frequen-
cies is a major ﬁnding, which is integrated into
risk appraisal processes. Accordingly, diﬀer-
ences in consumer numeracy skills are also a
possible key determinant in consumer risk
appraisal, as highlighted in previous work.46
Furthermore, percentages and natural frequen-
cies are not equivalent from a psychological
standpoint, despite the equivalent numerical
magnitude of risk.33 Thus, risk appraisal is not
purely restricted to the type of information
provided, but is also impacted by how infor-
mation is presented. Interestingly, Brewer
et al.47 have shown that females with higher
health literacy had an increased understanding
of various presentation formats used to convey
numerical risk information. However, it must
be noted that the present study did not quanti-
tatively assess consumer numeracy in conjunc-
tion with health literacy. Accordingly, a
quantitative examination of this potential
interplay is needed to explore population
health literacy and numeracy levels and their
implications for appropriate consumer treat-
ment side-eﬀect risk appraisal.
Many consumers could not gain meaning
from numerical side-eﬀect risk information. A
larger proportion of consumers preferred the
absence of numerical information, which may
be attributed to slight diﬀerences between the
table formats and the overwhelming magnitude
of numerical side-eﬀect risk information pre-
sented. FTT acknowledges that consumer
knowledge of the exact numerical side-eﬀect
risk may not be indicative of appropriate
consumer risk appraisal/understanding and
informed treatment decision making.28 Addi-
tionally, consumer preference for information
presentation formats does not necessarily
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correlate with comprehension.48,49 Interestingly,
in a study conducted by Knapp et al.,26 con-
sumers preferred side-eﬀect risk to be presented
using percentages and frequencies in combina-
tion, where this approach did not yield worse
estimates than using either alone. Evidently,
the complexities inherent in the presentation of
side-eﬀect risk information to consumers war-
rant further exploration.
Some consumer risk appraisal patterns were
comparable with explanations provided by psy-
chological theories. Consumer acknowledge-
ment that natural frequencies are easier to
understand is supported by FH. Diﬀering con-
sumer interpretation of risk highlights the role
of numeracy in how consumers encode and
appraise risk information via gist encoding, as
explained by FTT.29 High numeracy41 and
subjective numeracy50 have been shown to con-
tribute to improved gist understanding. Inter-
estingly, however, even though consumers
acknowledged that the information represented
a low numerical (verbatim or literal) side-eﬀect
risk, some consumers still regarded it as high
risk, which is in line with AH and the role that
subjective perceptions have in forming con-
sumer perspectives on risk. Consequently, a
plethora of existing factors inﬂuenced risk
perception.
Preferred numerical descriptors may diverge
between consumers,35 and perceived risk may
be dependent upon the numerical descriptor
utilized. With natural frequencies, some con-
sumers may picture patient cohorts and the
inherent risk being communicated without dif-
ﬁculty,51 where this possible realistic dimen-
sion may contribute to fear and anxiety.30
However, the impact of aﬀect-laden images
evoked from the use of natural frequencies
upon accurate risk appraisal is context depen-
dent52 and should be explored in further
detail.
Additionally, information framing played a
role in consumer understanding of side-eﬀect
risk. Consumers who could interconvert
between positively and negatively framed
numerical side-eﬀect risk information with ease
were more adept at ascertaining side-eﬀect
incidence, regardless of how the information
was framed. This ﬁnding is in agreement with
the notion that high numeracy decreases sus-
ceptibility to framing eﬀects.53
Importantly, consumers question numerical
risk information reliability when small denom-
inators are utilized.51 Regardless of denomina-
tor size, results of the present study indicate
that consumers want to ascertain the test pop-
ulation size. It follows on that consumers’
interest lies in ascertaining the likelihood of
experiencing side-eﬀects and their own individ-
ual risk, which may be inﬂuenced by previous
experiences of side-eﬀects, perception of health
status and understanding of numerical side-
eﬀect risk information, amongst other factors.
Therefore, negative framing may assist con-
sumers in ascertaining individual risk, as they
are accustomed to receiving negatively framed
side-eﬀect risk information. However, the non-
existence of ‘neutral framing’54 indicates that
the intention and motivation behind WMI
development is critical when addressing con-
sumer information needs and promoting
appropriate understanding. Consumer diﬀer-
ences inherent in risk appraisal will also play
a role in preferences for presentation of side-
eﬀect risk information, where a ‘one-size ﬁts
all’ approach may not be feasible.
Inclusion of benefit information
Beneﬁt information incorporated in V2 was
overlooked by consumers, which may have
been due to: minimal inclusion and emphasis
on beneﬁt information in comparison with the
side-eﬀects information and its integration
into the side-eﬀects section. Echoing gist
reasoning in FTT, many preferred positive
information without relevant numerical infor-
mation, as it is suﬃcient to establish a beneﬁt
proﬁle for the medicine (gist). It must be
stressed that the inclusion of beneﬁt informa-
tion within the side-eﬀects section is not the
sole, exhaustive method. The development of
a separate beneﬁt information WMI section
may be more beneﬁcial, promoting balanced
decision making.
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Limitations
As this study aimed to qualitatively explore
consumer opinions and understanding, the
results are not generalizable. Furthermore,
numerical data availability restricted the inclu-
sion of other descriptors and types of numeri-
cal side-eﬀect risk information. A medicine
bias may also be inherent, as only Tritace
and Plavix brand CMIs were revised. How-
ever, arguably, the side-eﬀects sections were the
focal point, rather than the study medicine
itself. Also, this study was not completely
accountable for the true behaviours of current
medicine users, and the age-speciﬁc inclusion
criteria may have excluded the opinions of
younger chronic medicine users. Additionally,
consumer health literacy was not assessed,
which limits the ability to draw conclusions on
its impact on understanding of side-eﬀect risk
information. Accordingly, this provides
grounds for future work to be conducted in the
area.
Conclusions
WMI design and relevant side-eﬀects informa-
tion play an inﬂuential role in consumer
appraisal. Consumers prefer tabulated side-
eﬀects in comparison with existing modes of
presentation in CMI. Complexities in risk pre-
sentation emphasize that the format and visual
assault of side-eﬀects information are impor-
tant considerations. Numerical expression used
to convey side-eﬀect risk information may fuel
diﬀering risk perception and understanding.
Psychological models do provide insight into
consumer risk appraisal processes. However,
varied consumer opinions and interpretation
of side-eﬀect risk information was apparent,
where consensus was not reached on a pre-
ferred and well-understood numerical risk
descriptor. Future studies should endeavour to
ascertain the concomitant impact of numeracy
and health literacy upon balanced decision
making and seek to address consumer misun-
derstandings. The challenge is to establish an
optimal way to present side-eﬀect risk informa-
tion to maximize understanding, by marrying
consumer needs and understanding with what
health-care professionals, manufacturers and
key stakeholders wish to convey.
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